Comparative Pharmacology
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus XTANDI.
TECENTRIQ HYBREZA vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
160 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic, PD-L1 Inhibitor
Antineoplastic